share_log

HC Wainwright & Co. Maintains Buy on SAB Biotherapeutics, Lowers Price Target to $1

Benzinga ·  Nov 14, 2023 13:46

HC Wainwright & Co. analyst Edward White maintains SAB Biotherapeutics (NASDAQ:SABS) with a Buy and lowers the price target from $2 to $1.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment